Contention-aware performance monitoring counter support for real-time MPSoCs

Tasks running in MPSoCs experience contention delays when accessing MPSoC’s shared resources, complicating task timing analysis and deriving execution time bounds. Understanding the Actual Contention Delay (ACD) each task suffers due to other corunning tasks, and the particular hardware shared resources in which contention occurs, is of prominent importance to increase confidence on derived execution time bounds of tasks. And, whenever those bounds are violated, ACD provides information on the reasons for overruns. Unfortunately, existing MPSoC designs considered in real-time domains offer limited hardware support to measure tasks’ ACD losing all these potential benefits. In this paper we propose the Contention Cycle Stack (CCS), a mechanism that extends performance monitoring counters to track specific events that allow estimating the ACD that each task suffers from every contending task on every hardware shared resource. We build the CCS using a set of specialized low-overhead Performance Monitoring Counters for the Cobham Gaisler GR740 (NGMP) MPSoC – used in the space domain – for which we show CCS’s benefits.The research leading to these results has received funding from the European Space Agency under contracts 4000109680, 4000110157 and NPI 4000102880, and the Ministry of Science and Technology of Spain under contract TIN-2015-65316-P. Jaume Abella has been partially supported by the Ministry of Economy and Competitiveness under Ramon y Cajal postdoctoral fellowship number RYC-2013-14717.Peer ReviewedPostprint (author's final draft

Muscle activation during gait in children with Duchenne muscular dystrophy

The aim of this prospective study was to investigate changes in muscle activity during gait in children with Duchenne muscular Dystrophy (DMD). Dynamic surface electromyography recordings (EMGs) of 16 children with DMD and pathological gait were compared with those of 15 control children. The activity of the rectus femoris (RF), vastus lateralis (VL), medial hamstrings (HS), tibialis anterior (TA) and gastrocnemius soleus (GAS) muscles was recorded and analysed quantitatively and qualitatively. The overall muscle activity in the children with DMD was significantly different from that of the control group. Percentage activation amplitudes of RF, HS and TA were greater throughout the gait cycle in the children with DMD and the timing of GAS activity differed from the control children. Significantly greater muscle coactivation was found in the children with DMD. There were no significant differences between sides. Since the motor command is normal in DMD, the hyper-activity and co-contractions likely compensate for gait instability and muscle weakness, however may have negative consequences on the muscles and may increase the energy cost of gait. Simple rehabilitative strategies such as targeted physical therapies may improve stability and thus the pattern of muscle activity

Contention-aware performance monitoring counter support for real-time MPSoCs

Tasks running in MPSoCs experience contention delays when accessing MPSoC’s shared resources, complicating task timing analysis and deriving execution time bounds. Understanding the Actual Contention Delay (ACD) each task suffers due to other corunning tasks, and the particular hardware shared resources in which contention occurs, is of prominent importance to increase confidence on derived execution time bounds of tasks. And, whenever those bounds are violated, ACD provides information on the reasons for overruns. Unfortunately, existing MPSoC designs considered in real-time domains offer limited hardware support to measure tasks’ ACD losing all these potential benefits. In this paper we propose the Contention Cycle Stack (CCS), a mechanism that extends performance monitoring counters to track specific events that allow estimating the ACD that each task suffers from every contending task on every hardware shared resource. We build the CCS using a set of specialized low-overhead Performance Monitoring Counters for the Cobham Gaisler GR740 (NGMP) MPSoC – used in the space domain – for which we show CCS’s benefits.The research leading to these results has received funding from the European Space Agency under contracts 4000109680, 4000110157 and NPI 4000102880, and the Ministry of Science and Technology of Spain under contract TIN-2015-65316-P. Jaume Abella has been partially supported by the Ministry of Economy and Competitiveness under Ramon y Cajal postdoctoral fellowship number RYC-2013-14717.Peer Reviewe

PROXIMA: A Probabilistic Approach to the Timing Behaviour of Mixed-Criticality Systems

International audienc

Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma

International audienceObjectives: The randomized controlled trial Inter-B-NHL ritux 2010 showed overall survival (OS) benefit and event-free survival (EFS) benefit with the addition of rituximab to standard Lymphomes Malins B (LMB) chemotherapy in children and adolescents with high-risk, mature B cell non-Hodgkin’s lymphoma. Our aim was to assess the cost-effectiveness of rituximab-chemotherapy versus chemotherapy alone in the French setting. Methods: We used a decision-analytic semi-Markov model with four health states and 1-month cycles. Resource use was prospectively collected in the Inter-B-NHL ritux 2010 trial (NCT01516580). Transition probabilities were assessed from patient-level data from the trial (n = 328). In the base case analysis, direct medical costs from the French National Insurance Scheme and life-years (LYs) were computed in both arms over a 3-year time horizon. Incremental net monetary benefit and cost-effectiveness acceptability curve were computed through a probabilistic sensitivity analysis. Deterministic sensitivity analysis and several sensitivity analyses on key assumptions were also conducted, including one exploratory analysis with quality-adjusted life years as the health outcome. Results: OS and EFS benefits shown in the Inter-B-NHL ritux 2010 trial translated into the model by rituximab-chemotherapy being the most effective and also the least expensive strategy over the chemotherapy strategy. The mean difference in LYs between arms was 0.13 [95% CI 0.02; 0.25], and the mean cost difference € − 3 710 [95% CI € − 17,877; € 10,525] in favor of rituximab-chemotherapy group. For a € 50,000 per LY willingness-to-pay threshold, the probability of the rituximab-chemotherapy strategy being cost-effective was 91.1%. All sensitivity analyses confirmed these findings. Conclusion: Adding rituximab to LMB chemotherapy in children and adolescents with high-risk mature B-cell non-Hodgkin's lymphoma is highly cost-effective in France. Trial registration: ClinicalTrials.gov identifier: NCT01516580

MACVIA-LR (Fighting Chronic Diseases for Active and Healthy Ageing in Languedoc-Roussillon): A Success Story of the European Innovation Partnership on Active and Healthy Ageing.

International audienceThe Région Languedoc Roussillon is the umbrella organisation for an interconnected and integrated project on active and healthy ageing (AHA). It covers the 3 pillars of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA): (A) Prevention and health promotion, (B) Care and cure, (C) and (D) Active and independent living of elderly people. All sub-activities (poly-pharmacy, falls prevention initiative, prevention of frailty, chronic respiratory diseases, chronic diseases with multimorbidities, chronic infectious diseases, active and independent living and disability) have been included in MACVIA-LR which has a strong political commitment and involves all stakeholders (public, private, patients, policy makers) including CARSAT-LR and the Eurobiomed cluster. It is a Reference Site of the EIP on AHA. The framework of MACVIA-LR has the vision that the prevention and management of chronic diseases is essential for the promotion of AHA and for the reduction of handicap. The main objectives of MACVIA-LR are: (i) to develop innovative solutions for a network of Living labs in order to reduce avoidable hospitalisations and loss of autonomy while improving quality of life, (ii) to disseminate the innovation. The three years of MACVIA-LR activities are reported in this paper

Introduction

International audienc

MACVIA-LR (Fighting Chronic Diseases for Active and Healthy Ageing in Languedoc-Roussillon) : a Success Story of the European Innovation Partnership on Active and Healthy Ageing

The R\ue9gion Languedoc Roussillon is the umbrella organisation for an interconnected and integrated project on active and healthy ageing (AHA). It covers the 3 pillars of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA): (A) Prevention and health promotion, (B) Care and cure, (C) and (D) Active and independent living of elderly people. All sub-activities (poly-pharmacy, falls prevention initiative, prevention of frailty, chronic respiratory diseases, chronic diseases with multimorbidities, chronic infectious diseases, active and independent living and disability) have been included in MACVIA-LR which has a strong political commitment and involves all stakeholders (public, private, patients, policy makers) including CARSAT-LR and the Eurobiomed cluster. It is a Reference Site of the EIP on AHA. The framework of MACVIA-LR has the vision that the prevention and management of chronic diseases is essential for the promotion of AHA and for the reduction of handicap. The main objectives of MACVIA-LR are: (i) to develop innovative solutions for a network of Living labs in order to reduce avoidable hospitalisations and loss of autonomy while improving quality of life, (ii) to disseminate the innovation. The three years of MACVIA-LR activities are reported in this paper